Degradation of activated protein kinases by ubiquitination

Annual Review of Biochemistry

Volumn 78, Issue , 2009, Pages 435-475

  Lu, Zhimin ^a   Hunter, Tony ^b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b SALK INSTITUTE FOR BIOLOGICAL STUDIES   (United States)

Author keywords

Activation; Downregulation; Phosphorylation; Ubiquitin

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE 7; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE 2; MITOGEN ACTIVATED PROTEIN KINASE KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE KINASE 4; MITOGEN ACTIVATED PROTEIN KINASE KINASE 6; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE 2; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE 4; MITOGEN ACTIVATED PROTEIN KINASE P38; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE; PROTEIN KINASE B; PROTEIN KINASE C; PROTEIN KINASE C ALPHA; PROTEIN KINASE C BETA; PROTEIN KINASE C DELTA; PROTEIN KINASE C ZETA; PROTEIN KINASE FYN; PROTEIN KINASE LYN; PROTEIN SERINE THREONINE KINASE; PROTEIN SH3; PROTEINASE; RAF PROTEIN; SERUM AND GLUCOCORTICOID REGULATED KINASE 1; UBIQUITIN; UNINDEXED DRUG;

CELL FUNCTION; DOWN REGULATION; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME DEGRADATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEPHOSPHORYLATION; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION; UBIQUITINATION;

ANIMALS; DOWN-REGULATION; HUMANS; PROTEIN KINASES; SIGNAL TRANSDUCTION; UBIQUITINATION;

EID: 67650744588     PISSN: 00664154     EISSN: 00664154     Source Type: Book Series    
DOI: 10.1146/annurev.biochem.013008.092711     Document Type: Review

References (250)

1. Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S. 2002. The protein kinase complement of the human genome. Science 298:1912-34
2. Blume-Jensen P, Hunter T. 2001. Oncogenic kinase signalling. Nature 411:355-65
3. Hunter T. 2000. Signaling-2000 and beyond. Cell 100:113-27
4. Oda A, Druker BJ, Ariyoshi H, Smith M, Salzman EW. 1993. pp60src is an endogenous substrate for calpain in human blood platelets. J. Biol. Chem. 268:12603-8
5. Karni R, Levitzki A. 2000. pp60(cSrc) is a caspase-3 substrate and is essential for the transformed phenotype of A431 cells. Mol. Cell Biol. Res. Commun. 3:98-104
6. Gervais FG, Thornberry NA, Ruffolo SC, Nicholson DW, Roy S. 1998. Caspases cleave focal adhesion kinase during apoptosis to generate a FRNK-like polypeptide. J. Biol. Chem. 273:17102-8
7. Carragher NO, Fincham VJ, Riley D, Frame MC. 2001. Cleavage of focal adhesion kinase by different proteases during SRC-regulated transformation and apoptosis. Distinct roles for calpain and caspases. J. Biol. Chem. 276:4270-75
8. Asselin E, Mills GB, Tsang BK. 2001. XIAP regulates Akt activity and caspase-3-dependent cleavage during cisplatin-induced apoptosis in human ovarian epithelial cancer cells. Cancer Res. 61:1862-68
9. Bachelder RE,Wendt MA, Fujita N, Tsuruo T, Mercurio AM. 2001. The cleavage of Akt/protein kinase B by death receptor signaling is an important event in detachment-induced apoptosis. J. Biol. Chem. 276:34702-7
10. Sun Y. 2003. Targeting E3 ubiquitin ligases for cancer therapy. Cancer Biol. Ther. 2:623-29
11. Pickart CM. 2000. Ubiquitin in chains. Trends Biochem. Sci. 25:544-48
12. Koegl M, Hoppe T, Schlenker S, Ulrich HD,Mayer TU, Jentsch S. 1999. A novel ubiquitination factor, E4, is involved in multiubiquitin chain assembly. Cell 96:635-44
13. Jin L,Williamson A, Banerjee S, Philipp I, Rape M. 2008. Mechanism of ubiquitin-chain formation by the human anaphase-promoting complex. Cell 133:653-65
14. Wang C, Deng L, Hong M, Akkaraju GR, Inoue J, Chen ZJ. 2001.TAK1 is a ubiquitin-dependent kinase of MKK and IKK. Nature 412:346-51
15. Deng L, Wang C, Spencer E, Yang L, Braun A, et al. 2000. Activation of the IκB kinase complex by TRAF6 requires a dimeric ubiquitin-conjugating enzyme complex and a unique polyubiquitin chain. Cell 103:351-61
16. Kirkin V, Dikic I. 2007. Role of ubiquitin- and Ubl-binding proteins in cell signaling. Curr. Opin. Cell Biol. 19:199-205
17. Hurley JH, Lee S, Prag G. 2006. Ubiquitin-binding domains. Biochem. J. 399:361-72
18. Woelk T, Oldrini B, Maspero E, Confalonieri S, Cavallaro E, et al. 2006. Molecular mechanisms of coupled monoubiquitination. Nat. Cell Biol. 8:1246-54
19. Al-Hakim AK, Zagorska A, Chapman L, Deak M, Peggie M, Alessi DR. 2008. Control of AMPK-related kinases by USP9X and atypical Lys(29)/Lys(33)-linked polyubiquitin chains. Biochem. J. 411:249-60
20. Hartmann-Petersen R, Gordon C. 2004. Integral UBL domain proteins: a family of proteasome interacting proteins. Semin. Cell Dev. Biol. 15:247-59
21. Ikeda F, Hecker CM, Rozenknop A, Nordmeier RD, Rogov V, et al. 2007. Involvement of the ubiquitinlike domain of TBK1/IKK-i kinases in regulation of IFN-inducible genes. EMBO J. 26:3451-62
22. Kuranaga E, Kanuka H, Tonoki A, Takemoto K, Tomioka T, et al. 2006. Drosophila IKK-related kinase regulates nonapoptotic function of caspases via degradation of IAPs. Cell 126:583-96
23. Kang BS, French OG, Sando JJ, Hahn CS. 2000. Activation-dependent degradation of protein kinase C eta. Oncogene 19:4263-72
24. Lu Z, Hornia A, Jiang Y-W, Zang Q, Ohno S, Foster DA. 1997. Tumor promotion by depleting cells of protein kinase Cδ. Mol. Cell Biol. 17:3418-28
25. Lu Z, Liu D, Hornia A, Devonish W, Pagano M, Foster DA. 1998. Activation of protein kinaseCtriggers its ubiquitination and degradation. Mol. Cell Biol. 18:839-45
26. Nakamura M, Tokunaga F, Sakata S, Iwai K. 2006. Mutual regulation of conventional protein kinase C and a ubiquitin ligase complex. Biochem. Biophys. Res. Commun. 351:340-47
27. Chen D, Gould C, Garza R, Gao T, Hampton RY, Newton AC. 2007. Amplitude control of protein kinase C by RINCK, a novel E3 ubiquitin ligase. J. Biol. Chem. 282:33776-87
28. Smith L,Wang Z, Smith JB. 2003. Caspase processing activates atypical protein kinaseCzeta by relieving autoinhibition and destabilizes the protein. Biochem. J. 375:663-71
29. Okuda H, Saitoh K, Hirai S, Iwai K, Takaki Y, et al. 2001. The von Hippel-Lindau tumor suppressor protein mediates ubiquitination of activated atypical protein kinase C. J. Biol. Chem. 276:43611-17
30. Srivastava J, Procyk KJ, Iturrioz X, Parker PJ. 2002. Phosphorylation is required for PMA- and cellcycle-induced degradation of protein kinase C delta. Biochem. J. 368:349-55
31. Blake RA, Garcia-Paramio P, Parker PJ, Courtneidge SA. 1999. Src promotes PKC δ degradation. Cell Growth Differ. 10:231-41
32. Lu Z, Xu S, Joazeiro C, Cobb MH, Hunter T. 2002. The PHD domain of MEKK1 acts as an E3 ubiquitin ligase and mediates ubiquitination and degradation of ERK1/2. Mol. Cell 9:945-56
33. Laine A, Ronai Z. 2005. Ubiquitin chains in the ladder of MAPK signaling. Sci. STKE 2005:re5
34. Liu WH, Lai MZ. 2005. Deltex regulates T-cell activation by targeted degradation of active MEKK1. Mol. Cell Biol. 25:1367-78
35. Yamashita M, Ying SX, Zhang GM, Li C, Cheng SY, et al. 2005. Ubiquitin ligase Smurf1 controls osteoblast activity and bone homeostasis by targeting MEKK2 for degradation. Cell 121:101-13
36. Manenti S, Delmas C, Darbon JM. 2002. Cell adhesion protects c-Raf-1 against ubiquitin-dependent degradation by the proteasome. Biochem. Biophys. Res. Commun. 294:976-80
37. Sheng J, Kumagai A, Dunphy WG, Varshavsky A. 2002. Dissection of c-MOS degron. EMBO J. 21:6061-71
38. Kuo WL, Duke CJ, Abe MK, Kaplan EL, Gomes S, Rosner MR. 2004. ERK7 expression and kinase activity is regulated by the ubiquitin-proteosome pathway. J. Biol. Chem. 279:23073-81
39. Dohlman HG, Thorner JW. 2001. Regulation of G protein-initiated signal transduction in yeast: paradigms and principles. Annu. Rev. Biochem. 70:703-54
40. Esch RK, Errede B. 2002. Pheromone induction promotes Ste11 degradation through aMAPK feedback and ubiquitin-dependent mechanism. Proc. Natl. Acad. Sci. USA 99:9160-65
41. Wang Y, Dohlman HG. 2002. Pheromone-dependent ubiquitination of the mitogen-activated protein kinase kinase Ste7. J. Biol. Chem. 277:15766-72
42. Collins CA,Wairkar YP, Johnson SL, DiAntonio A. 2006. Highwire restrains synaptic growth by attenuating a MAP kinase signal. Neuron 51:57-69
43. Joazeiro CA,Wing SS, Huang H, Leverson JD, Hunter T, Liu YC. 1999. The tyrosine kinase negative regulator c-Cbl as a RING-type, E2-dependent ubiquitin-protein ligase. Science 286:309-12
44. Waterman H, Levkowitz G, Alroy I, Yarden Y. 1999. The RING finger of c-Cbl mediates desensitization of the epidermal growth factor receptor. J. Biol. Chem. 274:22151-54
45. Swaminathan G,TsygankovAY. 2006. The Cbl family proteins: ring leaders in regulation of cell signaling. J. Cell Physiol. 209:21-43
46. Guenou H, Kaabeche K, Dufour C, Miraoui H, Marie PJ. 2006. Down-regulation of ubiquitin ligase Cbl induced by twist haploinsufficiency in Saethre-Chotzen syndrome results in increased PI3K/Akt signaling and osteoblast proliferation. Am. J. Pathol. 169:1303-11
47. Suzue N, Nikawa T, Onishi Y, Yamada C, Hirasaka K, et al. 2006. Ubiquitin ligase Cbl-b downregulates bone formation through suppression of IGF-I signaling in osteoblasts during denervation. J. Bone Miner. Res. 21:722-34
48. Adachi M, Katsumura KR, Fujii K, Kobayashi S, Aoki H, Matsuzaki M. 2003. Proteasome-dependent decrease in Akt by growth factors in vascular smooth muscle cells. FEBS Lett. 554:77-80
49. Riesterer O, Zingg D, Hummerjohann J, Bodis S, Pruschy M. 2004. Degradation of PKB/Akt protein by inhibition of the VEGF receptor/mTOR pathway in endothelial cells. Oncogene 23:4624-35
50. Medina EA, Afsari RR, Ravid T, Castillo SS, Erickson KL, Goldkorn T. 2005. Tumor necrosis factor-α decreases Akt protein levels in 3T3-L1 adipocytes via the caspase-dependent ubiquitination of Akt. Endocrinology 146:2726-35
51. Yan D, Guo L, Wang Y. 2006. Requirement of dendritic Akt degradation by the ubiquitin-proteasome system for neuronal polarity. J. Cell Biol. 174:415-24
52. Mao JH, Kim IJ,Wu D, Climent J, Kang HC, et al. 2008. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science 321:1499-502
53. Varfolomeev E, Blankenship JW, Wayson SM, Fedorova AV, Kayagaki N, et al. 2007. IAP antagonists induce autoubiquitination of c-IAPs, NF-κB activation, and TNFα-dependent apoptosis. Cell 131:669-81
54. Rothe M, Pan MG, Henzel WJ, Ayres TM, Goeddel DV. 1995. The TNFR2-TRAF signaling complex contains two novel proteins related to baculoviral inhibitor of apoptosis proteins. Cell 83:1243-52
55. Liao G, Zhang M, Harhaj EW, Sun SC. 2004. Regulation of the NF-κB-inducing kinase by tumor necrosis factor receptor-associated factor 3-induced degradation. J. Biol. Chem. 279:26243-50
56. He JQ, Zarnegar B, Oganesyan G, Saha SK, Yamazaki S, et al. 2006. Rescue of TRAF3-null mice by p100 NF-κB deficiency. J. Exp. Med. 203:2413-18
57. Belova L, Sharma S, Brickley DR, Nicolarsen JR, Patterson C, Conzen SD. 2006. Ubiquitin-proteasome degradation of serum- and glucocorticoid-regulated kinase-1 (SGK-1) is mediated by the chaperonedependent E3 ligase CHIP. Biochem. J. 400:235-44
58. Bogusz AM, Brickley DR, Pew T, Conzen SD. 2006. A novel N-terminal hydrophobic motif mediates constitutive degradation of serum- and glucocorticoid-induced kinase-1 by the ubiquitin-proteasome pathway. FEBS J. 273:2913-28
59. Zhou R, Snyder PM. 2005. Nedd4-2 phosphorylation induces serum and glucocorticoid-regulated kinase (SGK) ubiquitination and degradation. J. Biol. Chem. 280:4518-23
60. Hakak Y, Martin GS. 1999. Ubiquitin-dependent degradation of active Src. Curr. Biol. 9:1039-42
61. Harris KF, Shoji I, Cooper EM, Kumar S, Oda H, Howley PM. 1999. Ubiquitin-mediated degradation of active Src tyrosine kinase. Proc. Natl. Acad. Sci. USA 96:13738-43
62. 3 integrin-mediated signaling, cell adhesion, and osteoclast motility. J. Cell Biol. 152:181-95
63. Rao N, Dodge I, Band H. 2002. The Cbl family of ubiquitin ligases: critical negative regulators of tyrosine kinase signaling in the immune system. J. Leukoc. Biol. 71:753-63
64. Shao Y, Yang C, Elly C, Liu Y-C. 2004. Differential regulation of the B cell receptor-mediated signaling by the E3 ubiquitin ligase Cbl. J. Biol. Chem. 279:43646-53
65. Thien CB, Blystad FD, Zhan Y, Lew AM, Voigt V, et al. 2005. Loss of c-Cbl RING finger function results in high-intensity TCR signaling and thymic deletion. EMBO J. 24:3807-19
66. Echarri A, Pendergast AM. 2001. Activated c-Abl is degraded by the ubiquitin-dependent proteasome pathway. Curr. Biol. 11:1759-65
67. Smith JM, Mayer BJ. 2002. Abl: mechanisms of regulation and activation. Front. Biosci. 7:d31-42
68. Brasher BB, Van Etten RA. 2000. c-Abl has high intrinsic tyrosine kinase activity that is stimulated by mutation of the Src homology 3 domain and by autophosphorylation at two distinct regulatory tyrosines. J. Biol. Chem. 275:35631-37
69. Hantschel O, Superti-Furga G. 2004. Regulation of the c-Abl and Bcr-Abl tyrosine kinases. Nat. Rev. Mol. Cell Biol. 5:33-44
70. Cao C, Li Y, Leng Y, Li P, Ma Q, Kufe D. 2005. Ubiquitination and degradation of the Arg tyrosine kinase is regulated by oxidative stress. Oncogene 24:2433-40
71. MacGlashan D Jr, Miura K. 2004. Loss of syk kinase during IgE-mediated stimulation of human basophils. J. Allergy Clin. Immunol. 114:1317-24
72. Winberg G, Matskova L, Chen F, Plant P, Rotin D, et al. 2000. Latent membrane protein 2A of Epstein-Barr virus binds WW domain E3 protein-ubiquitin ligases that ubiquitinate B-cell tyrosine kinases. Mol. Cell Biol. 20:8526-35
73. Liu E, Cote JF, Vuori K. 2003. Negative regulation of FAK signaling by SOCS proteins. EMBO J. 22:5036-46
74. Sekine Y, Tsuji S, Ikeda O, Sugiyma K, Oritani K, et al. 2007. Signal-transducing adaptor protein-2 regulates integrin-mediated T cell adhesion through protein degradation of focal adhesion kinase. J. Immunol. 179:2397-407
75. Ungureanu D, Silvennoinen O. 2005. SLIM trims STATs: ubiquitin E3 ligases provide insights for specificity in the regulation of cytokine signaling. Sci. STKE 2005:pe49
76. Ali S, Nouhi Z, Chughtai N, Ali S. 2003. SHP-2 regulates SOCS-1-mediated Janus kinase-2 ubiquitination/ degradation downstream of the prolactin receptor. J. Biol. Chem. 278:52021-31
77. Nakayama KI, Nakayama K. 2006. Ubiquitin ligases: cell-cycle control and cancer. Nat. Rev. Cancer 6:369-81
78. DeSalle LM, Pagano M. 2001. Regulation of the G1 to S transition by the ubiquitin pathway. FEBS Lett. 490:179-89
79. Busino L, Bassermann F, Maiolica A, Lee C, Nolan PM, et al. 2007. SCFFbxl3 controls the oscillation of the circadian clock by directing the degradation of cryptochrome proteins. Science 316:900-4
80. Harper JW, Burton JL, Solomon MJ. 2002. The anaphase-promoting complex: it's not just for mitosis any more. Genes Dev. 16:2179-206
81. Nakayama KI, Hatakeyama S, Nakayama K. 2001. Regulation of the cell cycle at the G1-S transition by proteolysis of cyclin E and p27Kip1. Biochem. Biophys. Res. Commun. 282:853-60
82. Yew PR. 2001. Ubiquitin-mediated proteolysis of vertebrate G1- and S-phase regulators. J. Cell Physiol. 187:1-10
83. Liou YC, Ryo A, Huang HK, Lu PJ, Bronson R, et al. 2002. Loss of Pin1 function in the mouse causes phenotypes resembling cyclin D1-null phenotypes. Proc. Natl. Acad. Sci. USA 99:1335-40
84. Lin DI, Barbash O, Kumar KG,Weber JD, Harper JW, et al. 2006. Phosphorylation-dependent ubiquitination of cyclin D1 by the SCFFBX4-αB crystallin complex. Mol. Cell 24:355-66
85. Barbash O, Zamfirova P, Lin DI, Chen X, Yang K, et al. 2008. Mutations in Fbx4 inhibit dimerization of the SCFFbx4 ligase and contribute to cyclin D1 overexpression in human cancer. Cancer Cell 14:68-78
86. Welcker M, Clurman BE. 2008. FBW7 ubiquitin ligase: a tumour suppressor at the crossroads of cell division, growth and differentiation. Nat. Rev. Cancer 8:83-93
87. Möröy T, Geisen C. 2004. Cyclin E. Int. J. Biochem. Cell Biol. 36:1424-39
88. Singer JD, Gurian-West M, Clurman B, Roberts JM. 1999. Cullin-3 targets cyclin E for ubiquitination and controls S phase in mammalian cells. Genes Dev. 13:2375-87
89. Dealy MJ, Nguyen KV, Lo J, Gstaiger M, Krek W, et al. 1999. Loss of Cul1 results in early embryonic lethality and dysregulation of cyclin E. Nat. Genet. 23:245-48
90. Zhang YW, Otterness DM, Chiang GG, Xie W, Liu YC, et al. 2005. Genotoxic stress targets human Chk1 for degradation by the ubiquitin-proteasome pathway. Mol. Cell 19:607-18
91. Ohi MD, Feoktistova A, Ren L, Yip C, Cheng Y, et al. 2007. Structural organization of the anaphasepromoting complex bound to the mitotic activator Slp1. Mol. Cell 28:871-85
92. Peters JM. 2006. The anaphase promoting complex/cyclosome: a machine designed to destroy. Nat. Rev. Mol. Cell Biol. 7:644-56
93. Rodrigo-Brenni MC, Morgan DO. 2007. Sequential E2s drive polyubiquitin chain assembly on APC targets. Cell 130:127-39
94. Guardavaccaro D, Kudo Y, Boulaire J, Barchi M, Busino L, et al. 2003. Control of meiotic and mitotic progression by the F box protein β-Trcp1 in vivo. Dev. Cell 4:799-812
95. Moshe Y, Boulaire J, Pagano M, Hershko A. 2004. Role of Polo-like kinase in the degradation of early mitotic inhibitor 1, a regulator of the anaphase promoting complex/cyclosome. Proc. Natl. Acad. Sci. USA 101:7937-42
96. Amador V, Ge S, Santamaría PG, Guardavaccaro D, Pagano M. 2007. APC/CCdc20 controls the ubiquitin-mediated degradation of p21 in prometaphase. Mol. Cell 27:462-73
97. Song MS, Song SJ, Ayad NG, Chang JS, Lee JH, et al. 2004. The tumour suppressor RASSF1A regulates mitosis by inhibiting the APC-Cdc20 complex. Nat. Cell Biol. 6:129-37
98. Geley S, Kramer E, Gieffers C, Gannon J, Peters JM, Hunt T. 2001. Anaphase-promoting complex/cyclosome-dependent proteolysis of human cyclin A starts at the beginning of mitosis and is not subject to the spindle assembly checkpoint. J. Cell Biol. 153:137-48
99. Burton JL, Solomon MJ. 2007. Mad3p, a pseudosubstrate inhibitor of APCCdc20 in the spindle assembly checkpoint. Genes Dev. 21:655-67
100. Yu H. 2007. Cdc20: aWD40 activator for a cell cycle degradation machine. Mol. Cell 27:3-16
101. Fang G, Yu H, Kirschner MW. 1998. Direct binding of CDC20 protein family members activates the anaphase-promoting complex in mitosis and G1. Mol. Cell 2:163-71
102. Gorr IH, Boos D, Stemmann O. 2005. Mutual inhibition of separase and Cdk1 by two-step complex formation. Mol. Cell 19:135-41
103. Zachariae W, Nasmyth K. 1999. Whose end is destruction: cell division and the anaphase-promoting complex. Genes Dev. 13:2039-58
104. Li M, York JP, Zhang P. 2007. Loss of Cdc20 causes a securin-dependent metaphase arrest in two-cell mouse embryos. Mol. Cell Biol. 27:3481-88
105. Zur A, Brandeis M. 2001. Securin degradation is mediated by fzy and fzr, and is required for complete chromatid separation but not for cytokinesis. EMBO J. 20:792-801
106. Pesin JA, Orr-Weaver TL. 2008. Regulation of APC/C activators in mitosis and meiosis. Annu. Rev. Cell Dev. Biol. 24:475-99
107. Holt LJ, Hutti JE, Cantley LC, Morgan DO. 2007. Evolution of Ime2 phosphorylation sites on Cdk1 substrates provides a mechanism to limit the effects of the phosphatase Cdc14 in meiosis. Mol. Cell 25:689-702
108. Rape M, Kirschner MW. 2004. Autonomous regulation of the anaphase-promoting complex couples mitosis to S-phase entry. Nature 432:588-95
109. Listovsky T, Oren YS, Yudkovsky Y, Mahbubani HM, Weiss AM, et al. 2004. Mammalian Cdh1/Fzr mediates its own degradation. EMBO J. 23:1619-26
110. Benmaamar R, Pagano M. 2005. Involvement of the SCF complex in the control of Cdh1 degradation in S-phase. Cell Cycle 4:1230-32
111. Hames RS, Wattam SL, Yamano H, Bacchieri R, Fry AM. 2001. APC/C-mediated destruction of the centrosomal kinase Nek2A occurs in early mitosis and depends upon a cyclin A-type D-box. EMBO J. 20:7117-27
112. Myer DL, Bahassi el M, Stambrook PJ. 2005. The Plk3-Cdc25 circuit. Oncogene 24:299-305
113. Lindon C, Pines J. 2004. Ordered proteolysis in anaphase inactivates Plk1 to contribute to proper mitotic exit in human cells. J. Cell Biol. 164:233-41
114. Charles JF, Jaspersen SL,Tinker-Kulberg RL, Hwang L, Szidon A, Morgan DO. 1998. The Polo-related kinase Cdc5 activates and is destroyed by the mitotic cyclin destruction machinery in S. cerevisiae. Curr. Biol. 8:497-507
115. Morrow CJ,Tighe A, Johnson VL, Scott MI, Ditchfield C,Taylor SS. 2005. Bub1 and aurora B cooperate to maintain BubR1-mediated inhibition of APC/CCdc20. J. Cell Sci. 118:3639-52
116. Tang Z, Shu H, Oncel D, Chen S, Yu H. 2004. Phosphorylation of Cdc20 by Bub1 provides a catalytic mechanism for APC/C inhibition by the spindle checkpoint. Mol. Cell 16:387-97
117. Stewart S, Fang G. 2005. Destruction box-dependent degradation of aurora B is mediated by the anaphase-promoting complex/cyclosome and Cdh1. Cancer Res. 65:8730-35
118. Qi W, Yu H. 2007. KEN-box-dependent degradation of the Bub1 spindle checkpoint kinase by the anaphase-promoting complex/cyclosome. J. Biol. Chem. 282:3672-79
119. Wei W, Ayad NG, Wan Y, Zhang GJ, Kirschner MW, Kaelin WG Jr. 2004. Degradation of the SCF component Skp2 in cell-cycle phase G1 by the anaphase-promoting complex. Nature 428:194-98
120. Bashir T, Dorrello NV, Amador V, Guardavaccaro D, Pagano M. 2004. Control of the SCF(Skp2-Cks1) ubiquitin ligase by the APC/C(Cdh1) ubiquitin ligase. Nature 428:190-93
121. Liu W, Wu G, Li W, Lobur D, Wan Y. 2007. Cdh1-anaphase-promoting complex targets Skp2 for destruction in transforming growth factor β-induced growth inhibition. Mol. Cell Biol. 27:2967-79
122. Rodier G, Coulombe P,Tanguay PL, Boutonnet C, Meloche S. 2008. Phosphorylation of Skp2 regulated by CDK2 and Cdc14B protects it from degradation by APC(Cdh1) in G1 phase. EMBO J. 27:679-91
123. Watanabe N, Arai H, Nishihara Y, Taniguchi M, Watanabe N, et al. 2004. M-phase kinases induce phospho-dependent ubiquitination of somatic Wee1 by SCFβ-TrCP. Proc. Natl. Acad. Sci. USA 101:4419-24
124. Ayad NG, Rankin S, Murakami M, Jebanathirajah J, Gygi S, Kirschner MW. 2003. Tome-1, a trigger of mitotic entry, is degraded during G1 via the APC. Cell 113:101-13
125. Watanabe N, Arai H, Iwasaki J, Shiina M, Ogata K, et al. 2005. Cyclin-dependent kinase (CDK) phosphorylation destabilizes somaticWee1 via multiple pathways. Proc. Natl. Acad. Sci. USA 102:11663-68
126. Asano S, Park JE, Sakchaisri K, Yu LR, Song S, et al. 2005. Concerted mechanism of Swe1/Wee1 regulation by multiple kinases in budding yeast. EMBO J. 24:2194-204
127. Huang F, Kirkpatrick D, Jiang X, Gygi S, Sorkin A. 2006. Differential regulation of EGF receptor internalization and degradation by multiubiquitination within the kinase domain. Mol. Cell 21:737-48
128. Galcheva-Gargova Z, Theroux SJ, Davis RJ. 1995. The epidermal growth factor receptor is covalently linked to ubiquitin. Oncogene 11:2649-55
129. Yoon CH, Lee J, Jongeward GD, Sternberg PW. 1995. Similarity of sli-1, a regulator of vulval development in C. elegans, to the mammalian proto-oncogene c-cbl. Science 269:1102-5
130. Thien CB, Langdon WY. 2005. c-Cbl and Cbl-b ubiquitin ligases: substrate diversity and the negative regulation of signalling responses. Biochem. J. 391:153-66
131. Kassenbrock CK, Anderson SM. 2004. Regulation of ubiquitin protein ligase activity in c-Cbl by phosphorylation-induced conformational change and constitutive activation by tyrosine to glutamate point mutations. J. Biol. Chem. 279:28017-27
132. Kozlov G, Peschard P, Zimmerman B, Lin T, Moldoveanu T, et al. 2007. Structural basis for UBAmediated dimerization of c-Cbl ubiquitin ligase. J. Biol. Chem. 282:27547-55
133. Peschard P, Kozlov G, Lin T, Mirza IA, Berghuis AM, et al. 2007. Structural basis for ubiquitin-mediated dimerization and activation of the ubiquitin protein ligase Cbl-b. Mol. Cell 27:474-85
134. Longva KE, Blystad FD, Stang E, Larsen AM, Johannessen LE, Madshus IH. 2002. Ubiquitination and proteasomal activity is required for transport of the EGF receptor to inner membranes of multivesicular bodies. J. Cell Biol. 156:843-54
135. Fukazawa T, Miyake S, Band V, Band H. 1996. Tyrosine phosphorylation of Cbl upon epidermal growth factor (EGF) stimulation and its association with EGF receptor and downstream signaling proteins. J. Biol. Chem. 271:14554-59
136. Stang E, Johannessen LE, Knardal SL, Madshus IH. 2000. Polyubiquitination of the epidermal growth factor receptor occurs at the plasma membrane upon ligand-induced activation. J. Biol. Chem. 275:13940-47
137. de Melker AA,Van Der Horst G, Calafat J, Jansen H, Borst J. 2001. c-Cbl ubiquitinates theEGFreceptor at the plasma membrane and remains receptor associated throughout the endocytic route. J. Cell Sci. 114:2167-78
138. Umebayashi K, Stenmark H, Yoshimori T. 2008. Ubc4/5 and c-Cbl continue to ubiquitinate EGF receptor after internalization to facilitate polyubiquitination and degradation. Mol. Biol. Cell 19:3454-62
139. Levkowitz G,Waterman H, Zamir E, Kam Z, Oved S, et al. 1998. c-Cbl/Sli-1 regulates endocytic sorting and ubiquitination of the epidermal growth factor receptor. Genes Dev. 12:3663-74
140. Levkowitz G,Waterman H, Ettenberg SA, Katz M, Tsygankov AY, et al. 1999. Ubiquitin ligase activity and tyrosine phosphorylation underlie suppression of growth factor signaling by c-Cbl/Sli-1. Mol. Cell 4:1029-40
141. Frey MR, Dise RS, Edelblum KL, Polk DB. 2006. p38 kinase regulates epidermal growth factor receptor downregulation and cellular migration. EMBO J. 25:5683-92
142. Frederick L, Wang XY, Eley G, James CD. 2000. Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas. Cancer Res. 60:1383-87
143. Davies GC, Ryan PE, Rahman L, Zajac-Kaye M, Lipkowitz S. 2006. EGFRvIII undergoes activationdependent downregulation mediated by the Cbl proteins. Oncogene 25:6497-509
144. Marmor MD, Yarden Y. 2004. Role of protein ubiquitylation in regulating endocytosis of receptor tyrosine kinases. Oncogene 23:2057-70
145. Duan L, Miura Y, Dimri M, Majumder B, Dodge IL, et al. 2003. Cbl-mediated ubiquitinylation is required for lysosomal sorting of epidermal growth factor receptor but is dispensable for endocytosis. J. Biol. Chem. 278:28950-60
146. Felder S, Miller K, Moehren G, Ullrich A, Schlessinger J, Hopkins CR. 1990. Kinase activity controls the sorting of the epidermal growth factor receptor within the multivesicular body. Cell 61:623-34
147. Oved S, Mosesson Y, Zwang Y, Santonico E, Shtiegman K, et al. 2006. Conjugation to Nedd8 instigates ubiquitylation and down-regulation of activated receptor tyrosine kinases. J. Biol. Chem. 281:21640-51
148. Thiel KW, Carpenter G. 2007. Epidermal growth factor receptor juxtamembrane region regulates allosteric tyrosine kinase activation. Proc. Natl. Acad. Sci. USA 104:19238-43
149. Bao J, Alroy I, Waterman H, Schejter ED, Brodie C, et al. 2000. Threonine phosphorylation diverts internalized epidermal growth factor receptors from a degradative pathway to the recycling endosome. J. Biol. Chem. 275:26178-86
150. Fiorentino L, Pertica C, Fiorini M, Talora C, Crescenzi M, et al. 2000. Inhibition of ErbB-2 mitogenic and transforming activity by RALT, a mitogen-induced signal transducer which binds to the ErbB-2 kinase domain. Mol. Cell Biol. 20:7735-50
151. Shen F, Lin Q, Gu Y, Childress C, Yang W. 2007. Activated Cdc42-associated kinase 1 is a component of EGF receptor signaling complex and regulates EGF receptor degradation. Mol. Biol. Cell 18:732-42
152. Ettenberg SA, Magnifico A, Cuello M, Nau MM, Rubinstein YR, et al. 2001. Cbl-b-dependent coordinated degradation of the epidermal growth factor receptor signaling complex. J. Biol. Chem. 276:27677-84
153. Sorkin A. 2001. Internalization of the epidermal growth factor receptor: role in signalling. Biochem. Soc. Trans. 29:480-84
154. Balbis A, Parmar A, Wang Y, Baquiran G, Posner BI. 2007. Compartmentalization of signalingcompetent epidermal growth factor receptors in endosomes. Endocrinology 148:2944-54
155. Magnifico A, Ettenberg S, Yang C, Mariano J, Tiwari S, et al. 2003.WWdomain HECT E3s target Cbl RING finger E3s for proteasomal degradation. J. Biol. Chem. 278:43169-77
156. Thien CB, Langdon WY. 2001. Cbl: many adaptations to regulate protein tyrosine kinases. Nat. Rev. Mol. Cell Biol. 2:294-307
157. Naramura M, Jang IK, Kole H, Huang F, Haines D, Gu H. 2002. c-Cbl and Cbl-b regulate T cell responsiveness by promoting ligand-induced TCR down-modulation. Nat. Immunol. 3:1192-99
158. Thien CB, Walker F, Langdon WY. 2001. RING finger mutations that abolish c-Cbl-directed polyubiquitination and downregulation of the EGF receptor are insufficient for cell transformation. Mol. Cell 7:355-65
159. Zheng N,Wang P, Jeffrey PD, Pavletich NP. 2000. Structure of a c-Cbl-UbcH7 complex:RINGdomain function in ubiquitin-protein ligases. Cell 102:533-39
160. Schmidt MH, Husnjak K, Szymkiewicz I, Haglund K, Dikic I. 2006. Cbl escapes Cdc42-mediated inhibition by downregulation of the adaptor molecule βPix. Oncogene 25:3071-78
161. Sorkin A, Goh LK. 2008. Endocytosis and intracellular trafficking of ErbBs. Exp. Cell Res. 314:3093-106
162. Sigismund S,Woelk T, Puri C, Maspero E, Tacchetti C, et al. 2005. Clathrin-independent endocytosis of ubiquitinated cargos. Proc. Natl. Acad. Sci. USA 102:2760-65
163. Stang E, Blystad FD, Kazazic M, Bertelsen V, Brodahl T, et al. 2004. Cbl-dependent ubiquitination is required for progression of EGF receptors into clathrin-coated pits. Mol. Biol. Cell 15:3591-604
164. Chen C, Matesic LE. 2007. The Nedd4-like family of E3 ubiquitin ligases and cancer. Cancer Metastasis Rev. 26:587-604
165. de Melker AA, van der Horst G, Borst J. 2004. c-Cbl directs EGF receptors into an endocytic pathway that involves the ubiquitin-interacting motif of Eps15. J. Cell Sci. 117:5001-12
166. Fallon L, Belanger CM, Corera AT, Kontogiannea M, Regan-Klapisz E, et al. 2006. A regulated interaction with the UIM protein Eps15 implicates parkin in EGF receptor trafficking and PI(3)K-Akt signalling. Nat. Cell Biol. 8:834-42
167. Hoeller D, Crosetto N, Blagoev B, Raiborg C, Tikkanen R, et al. 2006. Regulation of ubiquitin-binding proteins by monoubiquitination. Nat. Cell Biol. 8:163-69
168. Polo S, Sigismund S, Faretta M, Guidi M, Capua MR, et al. 2002. A single motif responsible for ubiquitin recognition and monoubiquitination in endocytic proteins. Nature 416:451-55
169. Sigismund S, Argenzio E, Tosoni D, Cavallaro E, Polo S, Di Fiore PP. 2008. Clathrin-mediated internalization is essential for sustained EGFR signaling but dispensable for degradation. Dev. Cell 15:209-19
170. Katzmann DJ, Odorizzi G, Emr SD. 2002. Receptor downregulation and multivesicular-body sorting. Nat. Rev. Mol. Cell Biol. 3:893-905
171. Futter CE, Pearse A, Hewlett LJ, Hopkins CR. 1996. Multivesicular endosomes containing internalized EGF-EGF receptor complexes mature and then fuse directly with lysosomes. J. Cell Biol. 132:1011-23
172. Burke P, Schooler K, Wiley HS. 2001. Regulation of epidermal growth factor receptor signaling by endocytosis and intracellular trafficking. Mol. Biol. Cell 12:1897-910
173. Haj FG, Verveer PJ, Squire A, Neel BG, Bastiaens PI. 2002. Imaging sites of receptor dephosphorylation by PTP1B on the surface of the endoplasmic reticulum. Science 295:1708-11
174. Alwan HA, van Zoelen EJ, van Leeuwen JE. 2003. Ligand-induced lysosomal epidermal growth factor receptor (EGFR) degradation is preceded by proteasome-dependent EGFR deubiquitination. J. Biol. Chem. 278:35781-90
175. Kirisits A, Pils D, Krainer M. 2007. Epidermal growth factor receptor degradation: an alternative view of oncogenic pathways. Int. J. Biochem. Cell Biol. 39:2173-82
176. Kim BY, Olzmann JA, Barsh GS, Chin LS, Li L. 2007. Spongiform neurodegeneration-associated E3 ligase Mahogunin ubiquitylates TSG101 and regulates endosomal trafficking. Mol. Biol. Cell 18:1129-42
177. Babst M, Katzmann DJ, Estepa-Sabal EJ, Meerloo T, Emr SD. 2002. Escrt-III: an endosome-associated heterooligomeric protein complex required for mvb sorting. Dev. Cell 3:271-82
178. Kario E, Marmor MD, Adamsky K, Citri A, Amit I, et al. 2005. Suppressors of cytokine signaling 4 and 5 regulate epidermal growth factor receptor signaling. J. Biol. Chem. 280:7038-48
179. Jekely G, Rorth P. 2003. Hrs mediates downregulation of multiple signalling receptors in Drosophila. EMBO Rep. 4:1163-68
180. Klapper LN, Waterman H, Sela M, Yarden Y. 2000. Tumor-inhibitory antibodies to HER-2/ErbB-2 may act by recruiting c-Cbl and enhancing ubiquitination of HER-2. Cancer Res. 60:3384-88
181. Xu W, Marcu M, Yuan X, Mimnaugh E, Patterson C, Neckers L. 2002. Chaperone-dependent E3 ubiquitin ligase CHIP mediates a degradative pathway for c-ErbB2/Neu. Proc. Natl. Acad. Sci. USA 99:12847-52
182. Oster SK, Marhin WW, Asker C, Facchini LM, Dion PA, et al. 2000. Myc is an essential negative regulator of platelet-derived growth factor beta receptor expression. Mol. Cell Biol. 20:6768-78
183. Mori S, Heldin CH, Claesson-Welsh L. 1992. Ligand-induced polyubiquitination of the platelet-derived growth factor beta-receptor. J. Biol. Chem. 267:6429-34
184. Mori S, Heldin CH, Claesson-Welsh L. 1993. Ligand-induced ubiquitination of the platelet-derived growth factor beta-receptor plays a negative regulatory role in its mitogenic signaling. J. Biol. Chem. 268:577-83
185. Reddi AL,Ying G, Duan L, Chen G, DimriM,et al. 2007. Binding of Cbl to a phospholipaseCγ1-docking site on platelet-derived growth factor receptor β provides a dual mechanism of negative regulation. J. Biol. Chem. 282:29336-47
186. Crowley MR, Bowtell D, Serra R. 2005. TGF-β, c-Cbl, and PDGFR-α the in mammary stroma. Dev. Biol. 279:58-72
187. Cormont M, Meton I, Mari M, Monzo P, Keslair F, et al. 2003. CD2AP/CMS regulates endosome morphology and traffic to the degradative pathway through its interaction with Rab4 and c-Cbl. Traffic 4:97-112
188. Lennartsson J, Wardega P, Engström U, Hellman U, Heldin CH. 2006. Alix facilitates the interaction between c-Cbl and platelet-derived growth factor β-receptor and thereby modulates receptor downregulation. J. Biol. Chem. 281:39152-58
189. Masson K, Heiss E, Band H, Ronnstrand L. 2006. Direct binding of Cbl toTyr568 andTyr936 of the stem cell factor receptor/c-Kit is required for ligand-induced ubiquitination, internalization and degradation. Biochem. J. 399:59-67
190. Zeng S, Xu Z, Lipkowitz S, Longley JB. 2005. Regulation of stem cell factor receptor signaling by Cbl family proteins (Cbl-b/c-Cbl). Blood 105:226-32
191. Lee PS,Wang Y, Dominguez MG, Yeung YG, Murphy MA, et al. 1999. The Cbl protooncoprotein stimulates CSF-1 receptor multiubiquitination and endocytosis, and attenuates macrophage proliferation. EMBO J. 18:3616-28
192. Wilhelmsen K, Burkhalter S, van der Geer P. 2002. C-Cbl binds the CSF-1 receptor at tyrosine 973, a novel phosphorylation site in the receptor's carboxy-terminus. Oncogene 21:1079-89
193. Herbst R, Munemitsu S, Ullrich A. 1995. Oncogenic activation of v-kit involves deletion of a putative tyrosine-substrate interaction site. Oncogene 10:369-79
194. Ridge SA, Worwood M, Oscier D, Jacobs A, Padua RA. 1990. FMS mutations in myelodysplastic, leukemic, and normal subjects. Proc. Natl. Acad. Sci. USA 87:1377-80
195. Peschard P, Park M. 2003. Escape from Cbl-mediated downregulation: a recurrent theme for oncogenic deregulation of receptor tyrosine kinases. Cancer Cell 3:519-23
196. Ornitz DM, Itoh N. 2001. Fibroblast growth factors. Genome Biol. 2:reviews3005
197. Sorokin A, Mohammadi M, Huang J, Schlessinger J. 1994. Internalization of fibroblast growth factor receptor is inhibited by a point mutation at tyrosine 766. J. Biol. Chem. 269:17056-61
198. Kouhara H, Hadari YR, Spivak-Kroizman T, Schilling J, Bar-Sagi D, et al. 1997. A lipid-anchored Grb2-binding protein that links FGF-receptor activation to the Ras/MAPK signaling pathway. Cell 89:693-702
199. Hadari YR, Kouhara H, Lax I, Schlessinger J. 1998. Binding of Shp2 tyrosine phosphatase to FRS2 is essential for fibroblast growth factor-induced PC12 cell differentiation. Mol. Cell Biol. 18:3966-73
200. Ong SH, Guy GR, Hadari YR, Laks S, Gotoh N, et al. 2000. FRS2 proteins recruit intracellular signaling pathways by binding to diverse targets on fibroblast growth factor and nerve growth factor receptors. Mol. Cell Biol. 20:979-89
201. Wong A, Lamothe B, Lee A, Schlessinger J, Lax I, Li A. 2002. FRS2́ attenuates FGF receptor signaling by Grb2-mediated recruitment of the ubiquitin ligase Cbl. Proc. Natl. Acad. Sci. USA 99:6684-89
202. Cho JY, Guo C,Torello M, Lunstrum GP, Iwata T, et al. 2004. Defective lysosomal targeting of activated fibroblast growth factor receptor 3 in achondroplasia. Proc. Natl. Acad. Sci. USA 101:609-14
203. Peschard P, Park M. 2007. From Tpr-Met to Met, tumorigenesis and tubes. Oncogene 26:1276-85
204. Hammond DE, Carter S, McCullough J, Urbe S, Vande Woude G, Clague MJ. 2003. Endosomal dynamics of Met determine signaling output. Mol. Biol. Cell 14:1346-54
205. Carter S, Urbe S, Clague MJ. 2004. The met receptor degradation pathway: requirement for Lys48-linked polyubiquitin independent of proteasome activity. J. Biol. Chem. 279:52835-39
206. Kong-Beltran M, Seshagiri S, Zha J, Zhu W, Bhawe K, et al. 2006. Somatic mutations lead to an oncogenic deletion of met in lung cancer. Cancer Res. 66:283-89
207. Abella JV, Peschard P, Naujokas MA, Lin T, Saucier C, et al. 2005. Met/Hepatocyte growth factor receptor ubiquitination suppresses transformation and is required for Hrs phosphorylation. Mol. Cell Biol. 25:9632-45
208. Shattuck DL, Miller JK, Laederich M, Funes M, Petersen H, et al. 2007. LRIG1 is a novel negative regulator of the Met receptor and opposes Met and Her2 synergy. Mol. Cell Biol. 27:1934-46
209. Takeuchi T, Adachi Y, Sonobe H, Furihata M, Ohtsuki Y. 2006. A ubiquitin ligase, skeletrophin, is a negative regulator of melanoma invasion. Oncogene 25:7059-69
210. Penengo L, Rubin C, Yarden Y, Gaudino G. 2003. c-Cbl is a critical modulator of the Ron tyrosine kinase receptor. Oncogene 22:3669-79
211. Germano S, Barberis D, Santoro MM, Penengo L, Citri A, et al. 2006. Geldanamycins trigger a novel Ron degradative pathway, hampering oncogenic signaling. J. Biol. Chem. 281:21710-19
212. Laviola L, Natalicchio A, Giorgino F. 2007. The IGF-I signaling pathway. Curr. Pharm. Des. 13:663-69
213. Girnita L, Girnita A, Larsson O. 2003. Mdm2-dependent ubiquitination and degradation of the insulinlike growth factor 1 receptor. Proc. Natl. Acad. Sci. USA 100:8247-52
214. Vasilcanu R, Vasilcanu D, Rosengren L, Natalishvili N, Sehat B, et al. 2008. Picropodophyllin induces downregulation of the insulin-like growth factor 1 receptor: potential mechanistic involvement of Mdm2 and β-arrestin1. Oncogene 27:1629-38
215. Shan YX, Yang TL, Mestril R,Wang PH. 2003. Hsp10 and Hsp60 suppress ubiquitination of insulin-like growth factor-1 receptor and augment insulin-like growth factor-1 receptor signaling in cardiac muscle: implications on decreased myocardial protection in diabetic cardiomyopathy. J. Biol. Chem. 278:45492-98
216. Lai HC, Liu TJ, Ting CT, Yang JY, Huang L, et al. 2007. Regulation of IGF-I receptor signaling in diabetic cardiac muscle: dysregulation of cytosolic and mitochondria HSP60. Am. J. Physiol. Endocrinol. Metab. 292:E292-97
217. Itoh S, ten Dijke P. 2007. Negative regulation of TGF-beta receptor/Smad signal transduction. Curr. Opin. Cell Biol. 19:176-84
218. Glasgow E, Mishra L. 2008. Transforming growth factor-β signaling and ubiquitinators in cancer. Endocrinol. Relat. Cancer 15:59-72
219. Inman GJ, Nicolas FJ, Hill CS. 2002. Nucleocytoplasmic shuttling of Smads 2, 3, and 4 permits sensing of TGF-β receptor activity. Mol. Cell 10:283-94
220. ten Dijke P, Hill CS. 2004. New insights into TGF-β-Smad signalling. Trends Biochem. Sci. 29:265-73
221. Kang JS, Saunier EF, Akhurst RJ, Derynck R. 2008. The type I TGF-β receptor is covalently modified and regulated by sumoylation. Nat. Cell Biol. 10:654-64
222. Anders RA, Dore JJ Jr, Arline SL, Garamszegi N, Leof EB. 1998. Differential requirement for type I and type II transforming growth factor β receptor kinase activity in ligand-mediated receptor endocytosis. J. Biol. Chem. 273:23118-25
223. Ohashi N, Yamamoto T, Uchida C, Togawa A, Fukasawa H, et al. 2005. Transcriptional induction of Smurf2 ubiquitin ligase by TGF-β. FEBS Lett. 579:2557-63
224. Tajima Y, Goto K, Yoshida M, Shinomiya K, Sekimoto T, et al. 2003. Chromosomal region maintenance 1 (CRM1)-dependent nuclear export of Smad ubiquitin regulatory factor 1 (Smurf1) is essential for negative regulation of transforming growth factor-β signaling by Smad7. J. Biol. Chem. 278:10716-21
225. Levy L, Howell M, Das D, Harkin S, Episkopou V, Hill CS. 2007. Arkadia activates Smad3/Smad4-dependent transcription by triggering signal-induced SnoN degradation. Mol. Cell Biol. 27:6068-83
226. Nagano Y, Mavrakis KJ, Lee KL, Fujii T, Koinuma D, et al. 2007. Arkadia induces degradation of SnoN and c-Ski to enhance transforming growth factor-β signaling. J. Biol. Chem. 282:20492-501
227. Mavrakis KJ, Andrew RL, Lee KL, Petropoulou C, Dixon JE, et al. 2007. Arkadia enhances Nodal/TGF-β signaling by coupling Phospho-Smad2/3 activity and turnover. PLoS Biol. 5:e67
228. Moren A, Hellman U, Inada Y, Imamura T, Heldin CH, Moustakas A. 2003. Differential ubiquitination defines the functional status of the tumor suppressor Smad4. J. Biol. Chem. 278:33571-82
229. Lin X, Liang M, Liang YY, Brunicardi FC, Feng XH. 2003. SUMO-1/Ubc9 promotes nuclear accumulation and metabolic stability of tumor suppressor Smad4. J. Biol. Chem. 278:31043-48
230. Lee PS, Chang C, Liu D, Derynck R. 2003. Sumoylation of Smad4, the common Smad mediator of transforming growth factor-β family signaling. J. Biol. Chem. 278:27853-63
231. Imoto S, Sugiyama K, Muromoto R, Sato N, Yamamoto T, Matsuda T. 2003. Regulation of transforming growth factor-β signaling by protein inhibitor of activated STAT, PIASy through Smad3. J. Biol. Chem. 278:34253-58
232. Poncelet AC, Schnaper HW, Tan R, Liu Y, Runyan CE. 2007. Cell phenotype-specific down-regulation of Smad3 involves decreased gene activation as well as protein degradation. J. Biol. Chem. 282:15534-40
233. Penela P, Ribas C, Mayor F Jr. 2003. Mechanisms of regulation of the expression and function of G protein-coupled receptor kinases. Cell Signal 15:973-81
234. Elorza A, Penela P, Sarnago S, Mayor F Jr. 2003. MAPK-dependent degradation of G protein-coupled receptor kinase 2. J. Biol. Chem. 278:29164-73
235. Salcedo A, Mayor F Jr, Penela P. 2006. Mdm2 is involved in the ubiquitination and degradation of G-protein-coupled receptor kinase 2. EMBO J. 25:4752-62
236. Citri A,GanJ, Mosesson Y,Vereb G, Szollosi J,Yarden Y. 2004. Hsp90 restrains ErbB-2/HER2 signalling by limiting heterodimer formation. EMBO Rep. 5:1165-70
237. Citri A, Harari D, Shohat G, Ramakrishnan P, Gan J, et al. 2006. Hsp90 recognizes a common surface on client kinases. J. Biol. Chem. 281:14361-69
238. Xu W, Yuan X, Xiang Z, Mimnaugh E, Marcu M, Neckers L. 2005. Surface charge and hydrophobicity determine ErbB2 binding to the Hsp90 chaperone complex. Nat. Struct. Mol. Biol. 12:120-26
239. Esser C, Alberti S, Hohfeld J. 2004. Cooperation of molecular chaperones with the ubiquitin/proteasome system. Biochim. Biophys. Acta 1695:171-88
240. Blagosklonny MV. 2002. Hsp-90-associated oncoproteins: multiple targets of geldanamycin and its analogs. Leukemia 16:455-62
241. Lange BM, Rebollo E, Herold A, Gonzalez C. 2002. Cdc37 is essential for chromosome segregation and cytokinesis in higher eukaryotes. EMBO J. 21:5364-74
242. Wang H, Goode T, Iakova P, Albrecht JH, Timchenko NA. 2002. C/EBPalpha triggers proteasomedependent degradation of cdk4 during growth arrest. EMBO J. 21:930-41
243. Alberti S, Demand J, Esser C, Emmerich N, Schild H, Hohfeld J. 2002. Ubiquitylation of BAG-1 suggests a novel regulatory mechanism during the sorting of chaperone substrates to the proteasome. J. Biol. Chem. 277:45920-27
244. Demand J, Alberti S, Patterson C, Hohfeld J. 2001. Cooperation of a ubiquitin domain protein and an E3 ubiquitin ligase during chaperone/proteasome coupling. Curr. Biol. 11:1569-77
245. Song J, Takeda M, Morimoto RI. 2001. Bag1-Hsp70 mediates a physiological stress signalling pathway that regulates Raf-1/ERK and cell growth. Nat. Cell Biol. 3:276-82
246. Wang HG, Takayama S, Rapp UR, Reed JC. 1996. Bcl-2 interacting protein, BAG-1, binds to and activates the kinase Raf-1. Proc. Natl. Acad. Sci. USA 93:7063-68
247. Hwang JR, Zhang C, Patterson C. 2005. C-terminus of heat shock protein 70-interacting protein facilitates degradation of apoptosis signal-regulating kinase 1 and inhibits apoptosis signal-regulating kinase 1-dependent apoptosis. Cell Stress Chaperones 10:147-56
248. Daviau A, Proulx R, Robitaille K, Di Fruscio M, Tanguay RM, et al. 2006. Down-regulation of the mixed-lineage dual leucine zipper-bearing kinase by heat shock protein 70 and its cochaperone CHIP. J. Biol. Chem. 281:31467-77
249. Hunter T. 2007. The age of crosstalk: phosphorylation, ubiquitination, and beyond. Mol. Cell 28:730-38
250. Dai Z, Quackenbush RC, Courtney KD, Grove M, Cortez D, et al. 1998. Oncogenic Abl and Src tyrosine kinases elicit the ubiquitin-dependent degradation of target proteins through a Ras-independent pathway. Genes Dev. 12:1415-24